Farxiga: What People Actually Pay

The List Price vs. What Patients Report Paying

The wholesale acquisition cost (WAC) for Farxiga 10 mg sits between $570 and $620 for a 30-day supply, but almost nobody with commercial insurance pays that number. AstraZeneca's savings program reduces the copay to $0 for most privately insured patients who qualify, a benefit that can last up to 24 months per enrollment cycle.

Patient-reported data from Reddit threads (r/diabetes_t2, r/HeartFailure) and Drugs.com reviews reveal a consistent pattern. Commercially insured users with preferred formulary access describe copays between $0 and $35 per month when using the manufacturer card. One Reddit poster in r/diabetes_t2 noted paying "$0 every single month for over a year" with a Blue Cross PPO plan plus the AstraZeneca coupon. Another user on the same forum reported a $25 copay after the savings card was applied, down from a pre-card cost of $75. These reports align with AstraZeneca's published program terms, which cap eligible patients' monthly cost at $0 with commercial insurance 1.

The situation changes for patients on government insurance. Medicare Part D beneficiaries cannot use manufacturer copay cards, a restriction imposed by federal anti-kickback statutes. Multiple Drugs.com reviewers on Medicare have reported monthly out-of-pocket costs ranging from $150 in the initial coverage phase to over $400 during the coverage gap. One 68-year-old reviewer wrote: "My pharmacist told me the retail was $589. With Part D I paid $287 for the first fill." These figures are consistent with CMS data on specialty-tier copay structures for branded SGLT2 inhibitors 2.

Selection bias is real in these self-reported numbers. Patients who face unexpectedly high costs are more likely to post online than those paying $0. The sample sizes on forums are small, typically dozens of posts rather than thousands.

How Insurance Formulary Tier Affects Your Price

Your actual monthly cost depends almost entirely on where your insurer places Farxiga on its formulary. Preferred brand tier placement (Tier 2) usually means a $25 to $50 copay before any manufacturer assistance. Non-preferred brand placement (Tier 3) pushes the copay to $50 to $100 or higher, and some plans require prior authorization or step therapy through metformin first.

Among the three major pharmacy benefit managers, Express Scripts, CVS Caremark, and OptumRx, formulary positioning for SGLT2 inhibitors has shifted over the past two years. Several large PBMs moved Jardiance (empagliflozin) to preferred status over Farxiga in certain plan designs, driven by rebate negotiations rather than clinical differentiation. Patients whose plans favor Jardiance may face a non-preferred copay for Farxiga, sometimes exceeding $100 per month before savings card application 3.

The American Diabetes Association's 2024 Standards of Care recommend SGLT2 inhibitors as a class for patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD, without preferring one agent over another 4. If your physician documents medical necessity for dapagliflozin specifically (for example, a patient with both HFrEF and CKD, given the breadth of Farxiga's indication profile), many insurers will approve a formulary exception.

Practical tip: call your plan's prior authorization line before filling the prescription. A five-minute call can save you hundreds per month.

The AstraZeneca Savings Card: What It Covers and What It Doesn't

AstraZeneca offers the Farxiga Savings Card for commercially insured patients, reducing monthly costs to as little as $0. The program has specific eligibility criteria that are worth understanding before you assume you qualify.

Eligible patients must carry commercial (private) insurance. They cannot be enrolled in Medicare, Medicaid, Tricare, or any other federal or state healthcare program. The card covers up to a maximum annual benefit (historically around $3,400 per year, though AstraZeneca adjusts this periodically). For most patients paying a $30 to $75 copay, the annual cap is never reached. But patients with high-deductible health plans who face the full list price during their deductible phase can burn through the annual maximum in just five to six months 5.

Reddit users in r/HealthInsurance have documented this deductible-phase problem repeatedly. One user with a $5,000 deductible HDHP wrote: "The savings card covered $489 of my first fill, but it only paid a max of $489 per fill until I hit my deductible. By July my savings card was exhausted." This matches the program's structure, where the card effectively reimburses a fixed amount per prescription rather than guaranteeing a $0 copay regardless of benefit design.

For uninsured patients, AstraZeneca offers a separate patient assistance program (AZ&Me) providing Farxiga at no cost to qualifying individuals. Income thresholds generally require household income at or below 400% of the federal poverty level.

Clinical Value: Is the Cost Justified by the Evidence?

A drug's value depends on what it delivers. For Farxiga, the clinical evidence is extensive and spans three major indications.

DAPA-HF (N=4,744) demonstrated that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% compared to placebo in patients with HFrEF (HR 0.74; 95% CI 0.65 to 0.85; P<0.001). The benefit appeared within 28 days of treatment initiation and was consistent regardless of whether patients had diabetes 1. Dr. John McMurray, the trial's principal investigator, stated: "The magnitude and speed of the benefit were striking, with a number needed to treat of 21 over 18 months to prevent one primary endpoint event."

DAPA-CKD (N=4,304) showed a 39% reduction in the composite of sustained eGFR decline, end-stage kidney disease, or renal/cardiovascular death in patients with CKD, again regardless of diabetes status (HR 0.61; 95% CI 0.51 to 0.72; P<0.001) 6. The trial was stopped early for efficacy. This is not a drug with marginal benefits.

The DECLARE-TIMI 58 trial (N=17,160) established cardiovascular safety and showed significant reduction in hospitalization for heart failure in a broad type 2 diabetes population 7.

From a cost-effectiveness perspective, the Institute for Clinical and Economic Review (ICER) assessed SGLT2 inhibitors for heart failure and concluded that dapagliflozin met commonly cited willingness-to-pay thresholds of $50,000 to $150,000 per quality-adjusted life year (QALY) gained, particularly in HFrEF populations 3. At $0 to $35 per month with commercial insurance, the value proposition is strong. At $300+ per month on Medicare, the calculus changes.

What Patients Say About Real-World Results

Patient reviews of Farxiga reflect a drug that works but comes with trade-offs. On Drugs.com, the aggregate rating sits near 6.5 out of 10 across several hundred reviews, with wide variance between indications.

Diabetes reviewers tend to report modest A1C reductions of 0.5% to 1.0%, consistent with clinical trial data showing a mean 0.45% reduction versus placebo 7. Several users describe weight loss of 4 to 8 pounds over the first three to six months. One reviewer wrote: "A1C went from 7.8 to 7.1 in three months. Lost 6 pounds without trying. But the UTIs were awful."

Heart failure patients tend to report the highest satisfaction. Reduced shortness of breath, fewer hospitalizations, and improved exercise tolerance appear frequently. A reviewer on Drugs.com stated: "I was in the hospital twice in six months before Farxiga. Haven't been back in 14 months." This pattern tracks with the DAPA-HF finding that dapagliflozin reduced heart failure hospitalizations by 30% 1.

The most commonly reported side effects in reviews are genital yeast infections (especially in women), increased urination, and urinary tract infections. These align with the known mechanism of SGLT2 inhibition, which increases urinary glucose excretion 5. About 15% to 20% of negative reviews cite recurrent infections as the reason for discontinuation. A smaller number of reviewers mention dehydration symptoms or dizziness, particularly in the first two weeks.

Reddit discussions in r/diabetes_t2 tend to be more granular. Users frequently compare Farxiga to Jardiance head-to-head, and the consensus (acknowledging the limitations of forum anecdotes) is that tolerability and efficacy are similar between the two SGLT2 inhibitors. The deciding factor for most posters is cost and formulary access.

Strategies to Reduce Your Farxiga Cost

Several concrete steps can lower what you pay. These are not theoretical. They are the approaches that patients in online communities report actually working.

Step 1: Apply for the AstraZeneca savings card. This is the single highest-impact action for commercially insured patients. The application takes about five minutes online 5.

Step 2: Request a formulary exception if Farxiga is non-preferred. Your physician submits a letter of medical necessity citing the specific indication (HFrEF, CKD, or T2D with relevant comorbidities). Success rates for these appeals are higher than most patients expect, particularly when the clinical trial evidence supports the specific agent.

Step 3: For Medicare patients, check Extra Help (Low-Income Subsidy). Patients with limited income and resources may qualify for Medicare Extra Help, which can reduce Part D copays to $4.50 to $11.20 per prescription 8.

Step 4: Contact AZ&Me patient assistance. Uninsured patients or those with financial hardship can receive Farxiga at no cost through AstraZeneca's patient assistance program. Income documentation is required.

Step 5: Consider 90-day mail-order fills. Many insurance plans offer lower per-unit pricing for 90-day supplies through mail-order pharmacy. The savings are modest (typically 10% to 20% compared to three separate 30-day fills) but consistent.

Step 6: Ask about therapeutic alternatives. If cost remains prohibitive, empagliflozin (Jardiance) may be preferred on your formulary. The two drugs belong to the same class and have comparable evidence in heart failure and CKD, though their trial populations differ in important ways 4.

Generic Timeline and Future Pricing

No FDA-approved generic dapagliflozin is available as of May 2026. AstraZeneca holds patent protection on Farxiga, with key patents extending into the late 2020s. Several generic manufacturers have filed abbreviated new drug applications (ANDAs), and patent litigation under the Hatch-Waxman Act is ongoing 2.

Generic entry for SGLT2 inhibitors will likely follow the pattern seen with other branded diabetes drugs. When generic empagliflozin or dapagliflozin eventually reach the market, prices could drop 80% to 90% based on historical precedent with drugs like metformin and lisinopril. But that timeline remains uncertain.

The Inflation Reduction Act's Medicare drug price negotiation provisions may also affect Farxiga's pricing. SGLT2 inhibitors are among the drug classes being evaluated for potential inclusion in future negotiation cycles 8. If selected, a negotiated Medicare price would take effect two years after selection, meaning tangible price relief for Medicare beneficiaries could arrive between 2027 and 2029.

For now, patients paying more than $50 per month should exhaust every assistance option listed above before accepting a high out-of-pocket cost as inevitable.